What’s next for pay-for-delay after Supreme Court victory?
When the Supreme Court recently ruled that pay-for-delay agreements between brand and generic drug companies are subject to antitrust scrutiny, officials at the Federal Trade Commission had every right to feel...To view the full article, register now.
Already a subscriber? Click here to view full article